Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for December 1, 2020

11/30/2020

 
Regulatory Update
 
The FDA approved naxitamab (Danyelza, Y-mAbs Therapeutics), on 11/25/2020, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of relapsed or refractory high-risk neuroblastoma in bone or bone marrow.
 
The FDA approved setmelanotide (Imcivree, Rhythm Pharmaceuticals), on 11/27/2020, for chronic weight management of obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing.
 
The FDA has delayed approval of Revance’s daxibotulinumtoxinA due to travel restrictions delaying the inspection of the manufacturing plant. A new PDUFA date has not been announced.
 
The FDA rejected the NDA for Reata’s omaveloxolone for the treatment of Friedreich’s ataxia and requested additional data to strengthen data from the MOXIe trial.
 
The EMA accepted the MAA for EMD Serono’s tepotinib for the treatment of metastatic non-small cell lung cancer harboring METex14 skipping alterations.
 
Announced Research Updates
 
Immunocore announced interim data from a 378 patient, Phase III trial, where treatment with tebentafusp resulted in estimated overall survival of 73% compared to 58% with investigator choice (82% pembrolizumab; 12% ipilimumab; 6% dacarbazine) in patients with metastatic uveal melanoma.
 
UniQure announced that in the 26-week, 54 patient, Phase III, HOPE-B trial, a single dose of etranacogene dezaparvovec increased Factor IX activity from less than 2% at baseline to 37%.  While 72% of patients reported no bleeding episodes, 15 patients reported 21 bleeding episodes in adult males with severe or moderate-severe Hemophilia B.
 
Urovant announced that in a 12-week, 189 patient, Phase IIa trial, more patients treated with vibegron did not achieve at least a 30% improvement in average worst abdominal pain compared to placebo in women with abdominal pain due to irritable bowel syndrome (IBS) with IBS-D (diarrhea) and IBS-M (mixed IBS).
 
Published Research Updates
 
In a long term extension of the MUSE trial, 218 patients completed a total of 3 years of treatment with anifrolumab and maintained improvements in their SLE Disease Activity Index 2000 (SLEDAI-2K) scores and SLICC Damage Index (SDI) scores.
 
In the 52-week, 455 patient, Phase III, ESAX-DN trial, 22% of patients treated with esaxerenone achieved urinary albumin-to-creatinine ratio remission (< 30 mg/g creatinine and or > 30% reduction) compared to 4% with placebo in Japanese patients with type 2 diabetes and urinary albumin-to-creatinine ratio of 45 to < 300 mg/g creatinine treated with renin-angiotensin system inhibitors.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.